Company intelligence / Profile preview

Laurent Pharma

Montréal, Quebec, Canadalaurentpharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Laurent Pharma’s lead candidate, LAU‑7b, has completed a double-blind, randomized Phase 2 trial in adults with cystic fibrosis. The study showed statistically significant improvement in lung function and reduction of systemic inflammation compared to placebo. The drug also demonstrated benefit even when used alongside standard-of-care CFTR modulators. A separate Phase 2/3 trial (“ESSOR”) evaluates LAU‑7b for Long COVID patients to reduce disease burden on daily activities. Safety profile has been predictable with no unexpected serious adverse events reported.

Therapeutic areas: PulmonologyRare DiseasesInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

fenretinide

Phase 2

Indications: Cystic fibrosis, COVID-19

Beyond the preview

Go deeper on Laurent Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Laurent Pharma.

Explore the full profile